CUSIP No. 054754700
Page 3 of 5
Item 1(a) Name of Issuer
Aytu Bioscience, Inc. (the “Issuer”)
Item 1(b) Address of Issuer’s Principal Executive Offices
373 Inverness Parkway, Suite 206, Englewood, Colorado 80112
Item 2(a) Name of Person Filing
Cerecor Inc. (the “Reporting Person”)
Item 2(b) Address of Principal Business Office, or if none, Residence
540 Gaither Road, Suite 400, Rockville, Maryland 20850
Item 2(c) Citizenship
The Reporting Person is a Delaware company.
Item 2(d) Title of Class of Securities
Common Stock, $0.001 par value per share
Item 2(e) CUSIP Number
054754700
Item 3. Filing pursuant to Rules 13d-1(b) or 13d-2(b) or (c)
Not Applicable
Item 4. Ownership
On April 10, 2020 the Reporting Person converted 9,805,845 shares of the Issuer’s convertible preferred stock into 9,805,845 shares of the Issuer’s common stock, and became a 8.32% stockholder in the Issuer. As of the date of this filing, the Reporting Person does not own any shares of the Issuer’s common stock and therefore has 0% holdings in the Issuer.
(a) Amount beneficially owned:
0
(b) Percent of class:
0%
(c) Number of shares as to which such person has:
The Reporting Person has sole voting and dispositive power of 0 shares.
CUSIP No. 054754700
Page 4 of 5
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. X
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.